Author

Rohan Shah

Observed name: R. Shah

Institution: Aetion (United States)

Observed institutions: Aetion (United States), Novartis (United States)

OpenAlex ID: A5073762149

819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial

2022 · P. Nathan, J.J. Grob, et al. · Annals of Oncology · 3

Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.

2022 · Dirk Schadendorf, Axel Hauschild, et al. · Journal of Clinical Oncology · 3

Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib.

2023 · Zeynep Eroglu, Jackson Tang, et al. · Journal of Clinical Oncology · 1

SA60 No Claim Left Behind: Viability of Assessing Early Real-World Vaccine Effectiveness in Open and Closed Administrative Healthcare Claims

2025 · Neloufar Rahai, Rohan Shah, et al. · Value in Health

Development of Novel Progression Score to Quantify Disease Progression in Crohn’s Disease

2025 · Sirimon O’Charoen, Katherine Gilpin, et al. · Gastroenterology

Development of Novel Progression Score to Quantify Disease Progression in Crohn’s Disease

2025 · Sirimon O’Charoen, Katherine Gilpin, et al. · Inflammatory Bowel Diseases

Patient characteristics and real-world use of botulinum toxins for treatment of chronic sialorrhea

2024 · M. Hast, A. Kong, et al. · Parkinsonism & Related Disorders

Patient Characteristics and Real-world Use of Botulinum Toxins for Treatment of Chronic Sialorrhea (P4-3.017)

2024 · Michael Hast, Amanda Kong, et al. · Neurology

1118P Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy

2023 · T-G. Truong, S. Chandra, et al. · Annals of Oncology

POSTER: MDS-567 Real-World Analysis of a Large Electronic Medical Record Database of Patients With Higher-Risk Myelodysplastic Neoplasms (HR MDS): Treatment Profiles, Clinical Effectiveness, and Key Adverse Event Rates

2023 · Rohan Shah, Anusorn Thanataveerat, et al. · Clinical Lymphoma Myeloma & Leukemia

MDS-567 Real-World Analysis of a Large Electronic Medical Record Database of Patients With Higher-Risk Myelodysplastic Neoplasms (HR MDS): Treatment Profiles, Clinical Effectiveness, and Key Adverse Event Rates

2023 · Rohan Shah, Anusorn Thanataveerat, et al. · Clinical Lymphoma Myeloma & Leukemia

P746: Real-world Analysis of a Large Electronic Medical Record Database of Patients With Higher-risk Myelodysplastic Syndromes (hr Mds): Treatment Profiles, Clinical Effectiveness, and Key Adverse Events

2023 · Rohan Shah, Anusorn Thanataveerat, et al. · HemaSphere

Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma.

2022 · Sunandana Chandra, Evan Thomas Hall, et al. · Journal of Clinical Oncology

Real-world evaluation of the association between baseline metastatic patterns and clinical outcomes among patients with BRAF-positive metastatic melanoma.

2022 · Zeynep Eroglu, Sunandana Chandra, et al. · Journal of Clinical Oncology

Works count: 14

Citation count: 7

H-index: 2

I10-index: